DK3237423T3 - Thieno[2,3-c]pyrrol-4-on-derivater som erk-inhibitorer - Google Patents

Thieno[2,3-c]pyrrol-4-on-derivater som erk-inhibitorer Download PDF

Info

Publication number
DK3237423T3
DK3237423T3 DK15823869.1T DK15823869T DK3237423T3 DK 3237423 T3 DK3237423 T3 DK 3237423T3 DK 15823869 T DK15823869 T DK 15823869T DK 3237423 T3 DK3237423 T3 DK 3237423T3
Authority
DK
Denmark
Prior art keywords
thieno
pyrrol
derivatives
erk inhibitors
erk
Prior art date
Application number
DK15823869.1T
Other languages
English (en)
Inventor
Guillermo S Cortez
Sajan Joseph
Johnathan Alexander Mclean
William T Mcmillen
Michael John Rodriguez
Gaiying Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3237423T3 publication Critical patent/DK3237423T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
DK15823869.1T 2014-12-22 2015-12-16 Thieno[2,3-c]pyrrol-4-on-derivater som erk-inhibitorer DK3237423T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095185P 2014-12-22 2014-12-22
PCT/US2015/065940 WO2016106029A1 (en) 2014-12-22 2015-12-16 Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors

Publications (1)

Publication Number Publication Date
DK3237423T3 true DK3237423T3 (da) 2019-07-22

Family

ID=55135525

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15823869.1T DK3237423T3 (da) 2014-12-22 2015-12-16 Thieno[2,3-c]pyrrol-4-on-derivater som erk-inhibitorer

Country Status (44)

Country Link
US (3) US9469652B2 (da)
EP (1) EP3237423B1 (da)
JP (1) JP6445701B2 (da)
KR (1) KR101917972B1 (da)
CN (1) CN107108648B (da)
AR (1) AR102977A1 (da)
AU (1) AU2015369983C1 (da)
BR (1) BR112017011130A2 (da)
CA (1) CA2966559C (da)
CL (1) CL2017001514A1 (da)
CO (1) CO2017005217A2 (da)
CR (1) CR20170182A (da)
CY (1) CY1121831T1 (da)
DK (1) DK3237423T3 (da)
DO (1) DOP2017000122A (da)
EA (1) EA031659B1 (da)
EC (1) ECSP17038500A (da)
ES (1) ES2738406T3 (da)
GT (1) GT201700134A (da)
HR (1) HRP20191268T1 (da)
HU (1) HUE045933T2 (da)
IL (1) IL252065B (da)
JO (1) JO3596B1 (da)
LT (1) LT3237423T (da)
MA (1) MA41251B1 (da)
MD (1) MD3237423T2 (da)
ME (1) ME03490B (da)
MX (1) MX371206B (da)
MY (1) MY178426A (da)
NZ (1) NZ731531A (da)
PE (1) PE20171043A1 (da)
PH (1) PH12017501155A1 (da)
PL (1) PL3237423T3 (da)
PT (1) PT3237423T (da)
RS (1) RS59015B1 (da)
SG (1) SG11201704521SA (da)
SI (1) SI3237423T1 (da)
SV (1) SV2017005443A (da)
TN (1) TN2017000233A1 (da)
TR (1) TR201909887T4 (da)
TW (1) TWI704151B (da)
UA (1) UA119686C2 (da)
WO (1) WO2016106029A1 (da)
ZA (1) ZA201702786B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3052096B8 (en) 2013-10-03 2018-03-07 Kura Oncology, Inc. Inhibitors of erk and methods of use
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
JP6322770B2 (ja) 2014-12-22 2018-05-09 イーライ リリー アンド カンパニー Ｅｒｋ阻害剤
CA3001799A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2018005234A1 (en) * 2016-06-29 2018-01-04 Eli Lilly And Company Combination of erk1/2 inhibitor compound with gemcitabine or with gemcitabine and nab-paclitaxel for use in treatment of pancreatic cancer
WO2018081204A1 (en) * 2016-10-26 2018-05-03 Li George Y DEUTERATED N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL) PYRIDIN-2-YL)-5-FLUORO-4-(4-FLUORO-1-ISOPROPYL-2-METHYL-1H-BENZO[d]IMIDAZOL-6-YL)PYRIMIDIN-2-AMINE
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN111655690B (zh) 2017-11-24 2023-01-10 詹森药业有限公司 吡唑并吡啶酮化合物
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
CA3101117A1 (en) * 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
WO2020197917A1 (en) * 2019-03-27 2020-10-01 Eli Lilly And Company Salts of 5,6-dihydro-4h-thieno[2,3-c]pyrrol-4-one compound as erk inhibitors
CN113518779B (zh) * 2019-03-28 2024-03-15 江苏恒瑞医药股份有限公司 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
BR112021018924A2 (pt) * 2019-03-29 2022-02-01 Jiangsu Hengrui Medicine Co Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
CN113811303A (zh) * 2019-05-16 2021-12-17 伊莱利利公司 用于治疗brafv600e结直肠癌的erk1/2抑制剂与braf抑制剂和egfr抑制剂的三药组合
CN112457326B (zh) * 2019-09-06 2022-02-15 上海凌达生物医药有限公司 一类芳香杂环并内酰胺类化合物、制备方法和用途
EP4071152A4 (en) 2019-12-06 2024-01-17 D3 Bio Wuxi Co Ltd SPIRO COMPOUND SERVING AS AN ERK INHIBITOR AND THEIR USE
CN110950876B (zh) * 2019-12-10 2021-08-17 上海凌达生物医药有限公司 一类呋喃并内酰胺类化合物、制备方法和用途
WO2021216777A1 (en) * 2020-04-21 2021-10-28 The Trustees Of The Stevens Institute Of Technology Erk inhibitors for cancer therapy
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
WO2022068860A1 (zh) * 2020-09-29 2022-04-07 江苏恒瑞医药股份有限公司 一种吡咯并杂环类衍生物的晶型及其制备方法
KR20240024963A (ko) * 2021-06-28 2024-02-26 디3 바이오(우씨) 컴퍼니 리미티드 티아졸-락탐-스피로헤테로사이클릭 화합물 및 이의 적용
TW202332448A (zh) * 2021-11-15 2023-08-16 美商艾瑞斯卡公司 噻吩ulk1/2抑制劑及其用途
WO2023137297A2 (en) * 2022-01-11 2023-07-20 Suvalent Therapeutics, Inc. 5,6-dihydro-4h-thieno[2,3-c]pyrrole sumo inhibitors and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023048A1 (de) * 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
CA2422371C (en) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
CA2506773A1 (en) * 2002-11-04 2004-05-21 Vertex Pharmaceuticals Incorporated Heteroaryl-pyramidine derivatives as jak inhibitors
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
WO2007053776A1 (en) 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
CN102245600A (zh) * 2008-10-08 2011-11-16 百时美施贵宝公司 吡咯烷酮黑色素浓集激素受体-1拮抗剂
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
CA2809662C (en) * 2010-09-01 2019-04-16 Gilead Connecticut, Inc. Pyridazinones, method of making, and method of use thereof
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
SI2820009T1 (en) * 2012-03-01 2018-05-31 Array Biopharma, Inc. Serine / Threonine kinase inhibitors
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
JP6322770B2 (ja) * 2014-12-22 2018-05-09 イーライ リリー アンド カンパニー Ｅｒｋ阻害剤

Also Published As

Publication number Publication date
WO2016106029A1 (en) 2016-06-30
US9526733B1 (en) 2016-12-27
ES2738406T3 (es) 2020-01-22
ME03490B (me) 2020-01-20
CN107108648A (zh) 2017-08-29
AU2015369983C1 (en) 2019-02-21
IL252065B (en) 2020-08-31
KR101917972B1 (ko) 2018-11-12
UA119686C2 (uk) 2019-07-25
AR102977A1 (es) 2017-04-05
AU2015369983A1 (en) 2017-05-25
CA2966559C (en) 2019-06-18
LT3237423T (lt) 2019-08-26
US20160375030A1 (en) 2016-12-29
EP3237423A1 (en) 2017-11-01
IL252065A0 (en) 2017-07-31
DOP2017000122A (es) 2017-06-15
MX2017008242A (es) 2017-10-06
TR201909887T4 (tr) 2019-07-22
US9469652B2 (en) 2016-10-18
PE20171043A1 (es) 2017-07-19
EP3237423B1 (en) 2019-06-05
PH12017501155B1 (en) 2017-11-27
BR112017011130A2 (pt) 2017-12-26
CR20170182A (es) 2017-06-21
CN107108648B (zh) 2019-07-12
MY178426A (en) 2020-10-13
CO2017005217A2 (es) 2017-09-20
GT201700134A (es) 2018-11-23
HUE045933T2 (hu) 2020-01-28
HRP20191268T1 (hr) 2019-11-01
PL3237423T3 (pl) 2020-01-31
USRE48635E1 (en) 2021-07-13
CY1121831T1 (el) 2020-07-31
TWI704151B (zh) 2020-09-11
MA41251B1 (fr) 2019-09-30
MD3237423T2 (ro) 2019-11-30
CA2966559A1 (en) 2016-06-30
ZA201702786B (en) 2019-02-27
MA41251A (fr) 2017-11-01
SG11201704521SA (en) 2017-07-28
JO3596B1 (ar) 2020-07-05
EA031659B1 (ru) 2019-02-28
PT3237423T (pt) 2019-08-21
NZ731531A (en) 2018-12-21
ECSP17038500A (es) 2017-12-01
US20160176896A1 (en) 2016-06-23
JP2017538768A (ja) 2017-12-28
TN2017000233A1 (en) 2018-10-19
CL2017001514A1 (es) 2018-02-09
EA201791133A1 (ru) 2017-10-31
SV2017005443A (es) 2018-08-27
RS59015B1 (sr) 2019-08-30
KR20170083145A (ko) 2017-07-17
SI3237423T1 (sl) 2019-08-30
AU2015369983B2 (en) 2018-08-23
PH12017501155A1 (en) 2017-11-27
MX371206B (es) 2020-01-22
TW201632530A (zh) 2016-09-16
JP6445701B2 (ja) 2018-12-26

Similar Documents

Publication Publication Date Title
DK3237423T3 (da) Thieno[2,3-c]pyrrol-4-on-derivater som erk-inhibitorer
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
IL256265B (en) 3-tetrazolyl-benzene-2,1-disulfonamide derivatives as metallo-beta-lactamase inhibitors
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3204381T3 (da) N-pyridinylacetamidderivater som wnt-signaleringsbanehæmmere
DK3227297T3 (da) 4,6-substitueret-pyrazolo[1,5-a]pyraziner som janus kinase-inhibitorer
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
EP3394068A4 (en) TDO2 INHIBITORS
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
HK1246779A1 (zh) 作為磷酸肌醇3-激酶抑制劑的色烯衍生物
EP3186226A4 (en) Oxime sulfonate derivatives
EP3097088A4 (en) Icariin derivatives
HK1232227A1 (zh) 作為 抑制劑的喹嗪酮衍生物
EP3233858A4 (en) Erk inhibitors
HK1253572A1 (zh) 作為tnap抑制劑的吡啶並噁嗪酮化合物
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
EP3233859A4 (en) Erk inhibitors
DK3194408T3 (da) Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor
HK1254355A1 (zh) Bace1抑制劑2-氨基-7a-苯基-3，4，4a，5，7，7a-六氫呋喃並[3，4-b]吡啶
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
TH1601002954A (th) ออกตะไฮโดร-ไซโคลบิวตะ[1,2-c;3,4-c']ไดไพร์โรล-2-อิล ใหม่